Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor

Area of Science:

• Pharmacology
• Biochemistry
• Oncology

Background:

• Drug-metabolizing enzymes (DMEs) are crucial for drug efficacy and safety, especially in cancer therapy.
• Cytochrome P450 3A4 (CYP3A4) is a key DME, predominantly regulated by the human pregnane X receptor (hPXR).
• Dysregulation of DMEs contributes to adverse drug reactions, necessitating targeted interventions.

Purpose of the Study:

• To investigate Camptothecin (CPT) as a potential inhibitor of hPXR-mediated CYP3A4 regulation.
• To explore the therapeutic potential of modulating hPXR activity for cancer drug development.
• To evaluate the impact of CPT on drug metabolism and drug-drug interactions.

Main Methods:

• In vitro assays to assess hPXR transcriptional regulation of CYP3A4.
• Analysis of CPT's effects on hPXR-coactivator interactions, ligand binding, heterodimerization, and DNA binding.
• In vitro studies using human hepatocytes to evaluate CPT's effect on nifedipine metabolism in the presence of rifampicin (a CYP3A4 inducer).

Main Results:

• Camptothecin (CPT) demonstrated potent inhibition of hPXR-mediated CYP3A4 transcriptional regulation (IC50 = 0.58 microM).
• CPT disrupted the interaction between hPXR and steroid receptor coactivator-1, without affecting ligand binding or receptor heterodimerization.
• CPT treatment delayed nifedipine metabolism in human hepatocytes, indicating a potential to prevent drug-drug interactions mediated by CYP3A4 inducers.

Conclusions:

• Camptothecin (CPT) is a novel and potent inhibitor of hPXR, offering a new avenue for controlling CYP3A4 activity.
• CPT's ability to inhibit hPXR suggests a potential role in managing drug efficacy and preventing adverse drug reactions in cancer patients.
• These findings highlight the therapeutic potential of targeting hPXR with small molecules, particularly in the development of Camptothecin analogs for cancer therapy.